1. Hamilton JB. Patterned hair loss in man: types and incidence. Ann NY Acad Sci 1951;53:708-28.
2. Oslen EA. Disorders of Hair Growth: Diagnosis and Treatment. New York. McGraw-Hill, lnc 1994; 257-84
3. Montagna W, Ellis R. The Biology of Hair Growth. NY Academic Press 1958; 399-433.
4. Ishino A, Uzuka M, Tsuji Y et al.Progressive decrease in hair diameter in Japanese with male pattern baldness. J. Dermatol 1997; 24(12):758-64.
5. Hamilton JB. Patterned loss of hair in man: Types and incidence. Ann NY Acad Sci. 1951; 53:708-28.
6. Muller SA. Alopecia: Syndromes of genetic significance. J Invest Dermatol. 1973; 60:475-92.
7. Smith MA, Wells RS. Male type alopecia, alopecia areata and normal hair in women: Family histories. Arch Dermatol. 1964; 89:95-8.
8. Setty LR. Hair patterns of the scalp in white and Negro males. Am J Phys Anthropol. 1970; 33:49-55.
9. Tang PH, Chia HP, Cheong LL, Koh DA. community study of male androgenetic alopecia in Bishan, Singapore. Singapore Med J 2000; 41: 202–5.
10. Severi G, Sinclair R, Hopper JL etal. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors British Journal of Dermatology 2003; 149: 1207–1213.
11. Rhodes T, Girman CJ, Savin RC et al. Prevalence of male pattern hair loss in 18–49 year old men. Dermatol Surg 1998; 24: 1330–2.
12. Paik JH, Yoon JB, Sim WY et al. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol 2001; 145: 95–9.
13. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992;26:926-31.
14. Budd D, Himmelberger D, Rhodes T, et al. The effects of hair loss in European men: a survey in four countries. Eur J Dermatol 2000;10:122-7.
15. Lee HJ, Ha SJ, Kim D, et al. Perception of men with androgenetic alopecia by women and nonbalding men in Korea: how the nonbald regard the bald. Int J Dermatol 2002;41:867-9.
16. Passchier J. Quality of life issues in male pattern hair loss. Dermatology 1998;197:217-8.
17. Cotton SG, Nixon JM, Carpenter RG, et al. Factors discriminating men with coronary heart disease from healthy controls. Br Heart J 1972; 34: 458-64.
18. Herrera CR, D’Agostino RB, Gerstman BB, et al. Baldness and coronary heart disease rates in men from the Framingham Study. Am J Epidemiol 1995;142:828-33.
19. Ford ES, Freedman DS, Byers T. Baldness and ischemic heart disease in a national sample of men. Am J Epidemiol 1996;143:651-7.
20. Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial infarction in men. Jama 1993;269:998-1003.
21. Schnohr P, Lange P, Nyboe J, et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J 1995;130:1003-10.
22. Lotufo PA, Chae CU, Ajani UA, et al. Male pattern baldness and coronary heart disease: the Physicians’ Health Study. Arch Intern Med 2000;160:165-71.
23. Lotufo PA, Chae CU, Ajani UA, et al. Male pattern baldness and coronary heart disease: the Physicians’ Health Study. Arch Intern Med 2000;160:165-71.
24. Arias-Santiago S, Gutiérrez-Salmerón MT, Buendía-Eisman A etal. Hypertension and aldosterone levels in women with early-onset androgenetic alopecia British Journal of Dermatology 2010;162 (4): 786 - 789
25. Ahouansou S, Le Toumelin P, Crickx B, Descamps V. Association of androgenetic alopecia and hypertension. Eur J Dermatol. 2007; 17(3):220-2
26. Chen W, Yang CC, Chen GY, et al. Patients with a large prostate show a higher prevalence of androgenetic alopecia. Arch Dermatol Res 2004;296:245-9.
27. Oh BR, Kim SJ, Moon JD, et al. Association of benign prostatic hyperplasia with male pattern baldness. Urology 1998;51:744-8.
28. Hawk E, Brewslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol Biomark Prev 2000;9:523-7.
29. Giles GG, Severi G, Sinclair R, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002;11:549-53.
30. Ellis JA, Stebbing M, Harrap SB. Male pattern baldness is not associated with established cardiovascular risk factors in the general population. Clin Sci (Lond) 2001;100:401-4.
31. Denmark-WahnefriedW, Schildkraut JM, Thompson D, et al. Early onset baldness and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:325-8.
32. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002;2002:1-11.
33. Setty LR. Hair patterns of scalp of white and Negro males. Am J Phys Anthropol 1970;33:49-55.
34. Nyholt D.R., Gillespie N.A., Heath A.C., Martin N.G. Genetic basis of male pattern baldness. J. Invest. Dermatol. 2003;121:1561–1564.
35. Ellis JA, Harrap SB. The genetics of androgenetic alopecia. Clin Dermatol 2001;19:149-54.
36. Osborne D. Inheritance of baldness. J Hered 1916;347-55.
37. Kuster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol 1984;11:921-6.
38. Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol 1998;110:849-53.
39. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001;116:452-5.
40. Sawaya ME, Price VH. Different levels of 5 alpha reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J. Invest. Dermatol. 1997;109:296-300.
41. 39. 25. Yip L, Zaloumis S, Irwin D et al. "Gene-wide association study of the aromatase gene (CYP19A1) with female pattern hair loss" Br J Dermatol. 2009 ;161(2):289-94.
42. Hillmer AM, Flaquer A, Hanneken S et al. Genome- wide scan and Fine-Mapping Linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. The American Journal of Human genetics 2008;82:737-743.
43. Hillmer AM, Brockschmidt FF, Hanneken S, Eigelshoven S et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet. 2008 Nov;40(11):1279-81
44. Hamilton JB. Male hormone stimulation is prerequisite and an insitant in common baldness. AM J Anat. 1942;71:451-80.
45. Pits RL. Serum elevation of dihydroepiandrosterone sulphate associated with male pattern baldness in young men.J Am Acad dermatol 1987;16:571-3.
46. Jolanta B. Schmidt. Hormonal Basis of Male and Female Androgenic Alopecia: Clinical Relevance. Skin Pharmacol 1994;7:61-66.
47. Schmidt JB,Lindmaier A, Trenz A et al.Hormone studies in females with androgenetic hair loss. Gynecol Obstet Invest 1991; 31:235-9
48. Hamilton JB. Effect of castration in adolescent and young adult males upon further changes in the proportion of bare and hairy scalp. J Clin Endrocrinol Metabol 1960;20:1309-18.
49. Griffin JE, Wilson JD. The resistance syndromes: 5a reductase deficiency, testicular feminisation and related disorders. In:Baudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. edn. New York. McGraw Hill; 1989. p. 1919-44.
50. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186:1213-5.
51. Sinclair RD, Greenland K, van Egmond S, et al. Men with Kennedy’s disease have a reduced risk of androgenetic alopecia [unpublished observations]. In: St Vincent’s Hospital, Melbourne, Australia, 2007.
52. Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. II. Androstenedione metabolism in isolated hairs. J Clin Endocrinol Metab 1974;39:1012-9.
53. Randall VA, Thornton MJ, Hamada K, Messenger AG. Androgen action in cultured dermal papula cells from human hair follicles. Skin Pharmacol 1994; 7: 20–26.
54. Kaufman KD. Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 1996;14:697-711.
55. Jones LN, Sinclair RD, Rivett DE. Androgen metabolism and human hair growth.
Chem Aust 1997;64:12-3.
56. Itami S, Kurata S, Sonoda T, et al. Characterization of 5 alpha-reductase in cultured human dermal papilla cells from beard and occipital scalp hair. J Invest Dermatol 1991;96:57-60.
57. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic researchand clinical perspectives. J Invest Dermatol 2002;119:992-1007.
58. Bayne EK, Flanagan J, Einstein M, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol 1999;141:481-91.
59. Hoffmann R, Happle R. Current understanding of androgenetic alopecia. Part I: Etiopathogenesis European Journal of Dermatology. Volume 10, Number 4, 319-27.
60. Fritsch M, Orfanos CE, Zouboulis ChC: Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 116:793-800, 2001.
61. Itami S, Kurata S, Takayasu S. Androgen induction of follicular epithelial cell growth is mediated via insulin-like growth factor-I from dermal papilla cells. Biochem Biophys Res Commun 1995;212:988-94.
62. Shigeki Inui, Yoko Fukuzato, Takeshi Nakajima et al. Androgen-inducible TGF-from balding dermal papilla cells inhibits epithelial cell growth: a clue to understanding paradoxical effects of androgen on human hair growth][ Journal of Investigative Dermatology Symposium Proceedings (2003) 8, 69–71.
63. Thornton MJ, Hamada K, Messenger AG, et al. Androgen-dependent beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells. J Invest Dermatol 1998;111:727-32.
64. Randall VA, Thornton MJ, Messenger AG. Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol 1992;133:141-7.
65. Thornton MJ, Laing I, Hamada K, et al. Differences in testosterone metabolism by beard and scalp hair follicle dermal papilla cells. Clin Endocrinol (Oxf) 1993;39:633-9.
66. Itami S, Kurata S, Takayasu S. 5 alpha-reductase activity in cultured human dermal papilla cells from beard compared with reticular dermal fibroblasts. J Invest Dermatol 1990;94:150-2.
67. Boudou P, Reygagne P. Increased scalp skin and serum 5 alpha-reductase reduced androgens in a man relevant to the acquired progressive kinky hair disorder and developing androgenetic alopecia. Arch Dermatol 1997;133:1129-33.
68. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;109:296-300.
69. Orentreich N. Autografts in alopecias and other selected dermatological conditions.
Ann NY Acad Sci 1959;83:463-79.
70. Oslen E. A. Female pattern hair loss: Clinival features and potential hormonal factors. J AM Acad Dermatol 2001;45:570- 580.
71. Kligman AM. The human hair cycle. J Invest Dermatol 1959;33:307-16.
72. de Berker D A R, Messenger A G , Sinclair RD. Disorders of Hair. In Rook’s Textbook of Dermatology 7th Edition ( Volume 4) Burns T, Breathnach S, Cox N, Griffiths C( Eds) . Blackwell Publishing 2004. p 63.8 - 63.10.
73. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002;2002:1-11.
74. Courtois M, Loussouarn G, Hourseau C, Grollier JF. Hair cycle and alopecia. Skin Pharmacol 1994;7:84-9.
75. Guarrera M, Rebora A. Anagen hairs may fail to replace telogen hairs in early androgenetic alopecia. Dermatology 1996;192:28- 31.
76. Curtois M, Loussouarn G, Horseau C. Hair cycle and alopecia. Skin Pharmacol 1994;7:84-9.
77. Valerie A Randall, Tracey J Jenner, Nigel A Hibberts et al. Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles Journal of Endocrinology(2008)197,11-23
78. Jahoda CAB, Horne KA, Oliver RF. Induction of hair growth by implantation of cultured dermal papilla cells. Nature (London) 1984; 311:560–2.
79. Jahoda CAB, Reynolds AJ. Dermal–epidermal interactions. Adult follicle-derived cell populations and hair growth. Dermatol Clin 1996; 14:573–83.
80. Obana NJ, Uno H. Dermal papilla cells in macaque alopecia trigger a testosteronedependent inhibition of follicular cell proliferation. In:van Neste D, Randall VA, editors. Hair research in the next millennium. edn. Amsterdam. Elsevier; 1996. p. 307-10.
81. Randall VA. The use of dermal papilla cells in studies of normal and abnormal hair follicle biology. Dermatol Clin 1996;14:585-94.
82. Oliver RF, Jahoda CAB. The dermal papilla and the maintenance of hair growth. In:Rogers GA et al., editors. The biology of wool and hair. edn. London. Chapman and Hall; 1989. p. 51-67.
83. Van Scott EJ, Ekel TM. Geometric relationships between the matrix of the hair bulb and its dermal papilla in normal and alopecic scalp. J Invest Dermatol 1958;31:281-7.
84. Jahoda CA. Cellular and developmental aspects of androgenetic alopecia. Exp Dermatol 1998;7:235-48.
85. Elliott K, Stephenson TJ, Messenger AG. Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: Implications for the control of hair follicle size and androgen responses. J Invest Dermatol 1999;113:873-7.
86. Prieto VG, Sadick NS, Shea CR. Androgenetic alopecia: analysis of proliferation and apoptosis. Arch Dermatol 2002;138:1101-2.
88. Weger N, Schlake T. Igfbp3 Modulates Cell Proliferation in the Hair Follicle. Journal of Investigative Dermatology (2005) 125, 847–849;
89. Sinclair R. Male pattern androgenetic alopecia. BMJ 1998;317:865-9.
90. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol 2001;45:S81-6.
91. Whiting DA. Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia. Dermatol Ther 1998;8:24-33.
92. Pinkus H. Differential patterns of elastic fibers in scarring and non-scarring alopecias.
J Cutan Pathol 1978;5:93-104.
93. Yazdabadi A, Magee J, Harrison S, Sinclair R. The Ludwig pattern of androgenetic alopecia is due to a hierarchy of androgen sensitivity within follicular units that leads to selective miniaturization and a reduction in the number of terminal hairs per follicular unit. Br J Dermatol 2008; 159: 1300-1302.
94. Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol 1992 Sep;127(3):239-46.
95. Sueki H, Stoudemayer T, Kligman AM, Murphy GF. Quantitative and ultrastructural analysis of inflammatory infiltrates in male pattern alopecia. Acta Derm Venereol.1999 Sep;79(5):347-50.
96. Martin S. Z, Ralph M. T. Fibrosing Alopecia in a Pattern Distribution Patterned Lichen Planopilaris or Androgenetic Alopecia With a Lichenoid Tissue Reaction Pattern? Arch Dermatol. 2000;136:205-211.
97. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993 May;28(5 Pt 1):755-63
98. Sinclair R, Jolley D, Mallaric R, Mageed J. The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. J Am Acad Dermatol 2004 Volume 51, Issue 2, Pages 189-199.
99. Kligman AM. The comparative histopathology of male pattern baldness and senescent baldness. Clin Dermatol 1986;6:108-18.
100. A.G. Messenger and R. Sinclair. Follicular miniaturization in female pattern hair loss:
clinicopathological correlations . British Journal of Dermatology 2006 155, pp926–930
101. de Lacharrière O, Deloche C, Misciali C. Hair Diameter Diversity A Clinical Sign Reflecting the Follicle Miniaturization Arch Dermatol. 2001;137:641-646.
102. Hamilton JB. Patterned hair loss in man: types and incidence. Ann NY Acad Sci
103. Norwood OT. Male pattern baldness: classification and incidence. South Med J
104. Kosman ME. Evaluation of a new antihypertensive agent: minoxidil. JAMA 1980;244:73-5.
105. Devine Bl, Fife R, Trust PM. Minoxidil for severe hypertention after failure of other hypotensive agents. Br Med J 1977; 2: 667-9.
106. Jacobs D. Minoxidil Experience in Australia 1974-1980. Med J Aust 1981; 1:477-8.
107. Pennisi AJ, Takahashi M, Bernstein BH et al. Minoxidil therapy in children with severe hypertension. J Paediatr 1977;90:813-9.
108. Kreindler TG. Topical minoxidil in early androgenetic alopecia. J Am Acad Dermatol 1987;16:718-24.
109. Wester RC, Maibach HI, Guy RH, Nowak E. Minoxidil stimulates cutaneous blood flow in human balding scalp:Pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 1984;82:515-7.
110. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998;138:407-411.
111. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600.
112. Buhl AE, Conrad SJ, Waldon DJ et al. Pottasium channel conductance as a control mechanism in hair follicles. J Invest Dermatol 1993;101:148s-52s.
113. 106. 51. Buhl AE, Waldon DJ, Conrad SJ et al. Pottasium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992;98:315-19.
114. Katz HI, Hien NT, Prawer SE, et al. Long-term efficacy of topical minoxidil in male
pattern baldness. J Am Acad Dermatol 1987;16:711-8.
115. 108. 75 Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol 1987;16:677-85.
116. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999;41:717-21.
117. Olsen EA, Weiner MS, Amara IA, et al. Five-year follow-up of men with androgenetic
alopecia treated with topical minoxidil. J Am Acad Dermatol 1990;22:643-6.
118. 111. [39 Olsen, E.A. and Weiner, M.S. (1987) Topical minoxidil in male pattern baldness:
effects of discontinuation of treatment. J. Am. Acad. Dermatol. 17, 97–101]
119. Roberts JL. Androgenetic alopecia: treatment results with topical minoxidil. J Am Acad Dermatol 1987;16:705-10.
120. Olsen, E.A. et al. A multicenter, randomized, placebo-controlled, doubleblind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J. Am. Acad. Dermatol. (2007) ; 57: 767–774.
121. Friedman ES, Friedman PM,Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution:atiology and treatment. J Am Acad dermatol 2002;46:309-12.
122. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am AcadDermatol 1998;39:578-89.
123. 116. 81 Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in
men with androgenetic alopecia. Br J Dermatol 2000;143:804-10.
124. Whiting DA, Waldstreicher J, Sanchez M, et al. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc 1999;4:282-4.
125. Price VH, Menefee E, Sanchez M, et al. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 2002;46:517-23.
126. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999;41:550-4.
127. Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999;41:555-63.
128. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal
male pattern hair loss. J Am Acad Dermatol 1999;40:930-7.
129. The Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational
experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002;12:38-49.
130. Stough DB, Rao NA, Kaufman KD, et al. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 2002;12:32-7.
131. Price VH, Menefee E, Sanchez M, et al. Changes in hair weight in men with androgenetic
alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol 2006;55:71-4.
132. Arca E, Açikgöz G, Taştan HB, Köse O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology. 2004;209(2):117-25.
133. Tosti A, Piraccini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. J Eur Acad Dermatol Venereol 2001;15:418-21.
134. Matzkin H, Barak M, Braf Z. Effect of finasteride on free and total serum prostatespecific
antigen in men with benign prostatic hyperplasia. Br J Urol 1996;78:405-8.
135. Keetch DW, Andriole GL, Ratliff TL, et al. Comparison of percent free prostatespecific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology 1997;50:901-5.
136. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998;52:195-201.
137. Physicians circular for Propecia. West Point, NY: Merck; December 1997.
138. Marks LS, Andriole GL, Fitzpatrick JM, et al. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006;176:868-74.
139. Etzioni R, Howlander N, Shaw P et al. LONG-TERM EFFECTS OF FINASTERIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIAL. Journal of Urology, The, Volume 174, Issue 3, Pages 877-881
140. Amico AD , Roehrborn C. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial .The Lancet Oncology, Volume 8, Issue 1, Pages 21-25
141. Guess HA , Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. The Prostate Volume 22 Issue 1, Pages 31 – 37.
142. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the
development of prostate cancer. N Engl J Med 2003;349:215-24.
144. Lucia MS, Epstein JI, Goodman PJ et al. Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 2007 99(18):1375-1383.
145. Lucia MS, Epstein JI, Goodman PJ, et al: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1375–1383, 2007.
146. Cohen YC, Liu KS, Heyden NL, et al: Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1366–1374, 2007.
147. Kramer BS, Hagerty KL, Justman S et al. Use of 5--Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline . Journal of Clinical Oncology, Vol 27, No 9 (March 20), 2009: pp. 1502-1516.
148.Elliott CS, Shinghal R, Presti JC The Influence of Prostate Volume on Prostate-Specific Antigen Performance: Implications for theProstate Cancer Prevention Trial Outcomes Clin. Cancer Res., July 15, 2009; 15(14): 4694 - 4699.
149.Redman MW,Tangen CM, Goodman PJ et al. Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach Cancer Prevention Research, August 1, 2008; 1(3): 174 - 181.
150. Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity
of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749-52.
151. Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol
152. Trueb RM, Itin P. Photographic documentation of the effectiveness of 1 mg. oral finasteride
in treatment of androgenic alopecia in the man in routine general practice in Switzerland]. Schweiz Rundsch Med Prax 2001;90:2087-93.
153. Tollin SR, Rosen HN, Zurowski K, et al. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study. J Clin Endocrinol Metab 1996;81:1031-4.
154. Matsumoto AM, Tenover L, McClung M, et al. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002;167:2105-8.
155. Wade MS, Sinclair RD. Reversible painful gynaecomastia induced by low dose finasteride (1 mg/day). Australas J Dermatol 2000;41:55.
156. Ferrando J, Grimalt R, Alsina M, et al. Unilateral gynecomastia induced by treatment
with 1 mg of oral finasteride. Arch Dermatol 2002;138:543-4.
157. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A Finasteride induced depression: a prospective study. Clin Pharmacol. 2006; 6: 7
158. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179-84.
159. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual
5-alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89: 2179-84.
160.Dallob AL, Sadick NS, Unger W et al. The effect of finasteride, a 5-alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metabol 1994;79:703-6.
161. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006;55:1014-23.
162. Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-94.
163. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005;4:637-40.
164. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, et al. The effect of 5alpha reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007;92:1659-65.
165. Andriole GL, Kirby R. Safety and tolerability of the dual 5- alpha reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8.
166. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202.
167. Fleshner N, Gomella LG, Cookson MS et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov;28(6):763-9. Epub 2007 May 29.
168. Sovak M, Seligson AL, Kucerova R, et al. Fluridil, a rationally designed topical
agent for androgenetic alopecia: first clinical experience. Dermatol Surg 2002;28:678-85.
169. Wolf, R. et al. Prostaglandin analogs for hair growth: great expectations. Dermatol. Online J. (2003) 9, 7
170. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol. 2002;82(1):7-12.
171. Ge Piérard, Piérard-Franchimont C , Nikkels-Tassoudji N et al. Improvement in the inflammatory aspect of androgenetic alopecia. A pilot study with an antimicrobial lotion. Journal of Dermatological Treatment1996, Vol. 7, No. 3, Pages 153-157
172.Inui S, Itami S. Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity. J Dermatol Sci 2007;45:66-8.
173. Hugo Perez, B.S. (2004) Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med. Hypotheses 62, 112–115.
174. Danilenko DM, BD Ring BD, D Yanagihara D et al. Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia. American Journal of Pathology, Vol 147, 145-154.
175. McElwee KJ, Huth A, Sabine Kissling S , Hoffmann R. Macrophage-Stimulating Protein Promotes Hair Growth Ex Vivo and Induces Anagen from Telogen Stage Hair Follicles In Vivo. Journal of Investigative Dermatology (2004) 123, 34–40.
176. Okuda S. The study of clinical experiments of hair transplantation. Jpn J Dermatolurol. 1939;46:135
177. Orentreich N. Autografts in alopecias and other selected dermatological conditions..Ann N Y Acad Sci. 1959 Nov 20;83:463-79.
178. Bernstein RM, Rassman WR, Szaniawski W, Halperin A: Follicular Transplantation. Intl J Aesthetic Restorative Surgery 1995; 3: 119-32
179. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002 Aug;29(8):489-9.
180. Kassimir JJ. Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study. J Am Acad Dermatol 1987;16:685-7.
181. Roenigk HH, Berman MD. Topical 2% minoxidil with hair transplantation. Face 1993;4:213-6.
182. Leavitt M, Perez-Meza D, Rao NA et al. Effects of finasteride (1 mg) on hair transplant. J Dermatol Surg 2005;31:1268-76.